THBS1 Complex Biomarker Detection for Early Breast Cancer Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for breast cancer screening, such as CA15-3 and CA27.29, have low sensitivity, especially in populations like Taiwanese women, and existing methods like ELISA assays and western blotting are limited by high background noise and labor-intensive procedures, making it difficult to accurately quantify low-abundance protein complexes associated with early-stage breast cancer.
Innovation Solution
The use of automated capillary electrophoresis and immunodetection to detect and quantify thrombospondin-1 (THBS1) complex structures in plasma samples, employing a capture reagent like antibodies, to determine biomarker values indicative of breast cancer risk or presence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ELISA assays are used to detect biomarker protein complexes, then immunochemical detection is achieved, but high background noises mask the signals from low-abundance complex structures
Solution Approach 1:
The patent segments the detection process into two distinct stages: first separating protein complexes by size via gel electrophoresis, then detecting specific complexes through immunodetection. This segmentation allows the signal from low-abundance complexes to be isolated from the high background noise that plagues direct ELISA assays.
Solution Approach 2:
The patent introduces gel electrophoresis as an intermediary step between sample preparation and immunodetection. This intermediary separates protein complexes by molecular weight, allowing specific complexes to be isolated and detected with reduced background interference, thereby improving measurement precision.
2Measurement precision
If western blotting is used to detect protein complexes, then detection capability is provided, but labor-intensive procedures and inconsistent electro-transfer efficiency limit accuracy
Solution Approach 1:
The patent employs automated capillary electrophoresis systems that self-regulate the separation and detection processes, reducing manual intervention. The system automatically performs gel electrophoresis, transfers proteins to membranes, and conducts immunodetection, eliminating the labor-intensive manual steps inherent in traditional western blotting while maintaining consistent results.
Solution Approach 2:
The patent replaces the manual mechanical procedures of traditional western blotting with automated capillary electrophoresis technology. This substitution eliminates inconsistent electro-transfer efficiency by using standardized capillary formats and automated control systems, thereby improving both ease of operation and measurement precision.
3Reliability
If traditional biomarkers like CA15-3 and CA27.29 are used for breast cancer screening, then screening capability is provided, but sensitivity is low especially in Taiwanese population
Solution Approach 1:
The patent changes the detection parameters by targeting thrombospondin-1 complex structures with specific molecular weights (180 kDa and 410 kDa) instead of traditional biomarkers. This parameter change—detecting specific protein complex sizes rather than general biomarker presence—results in significantly improved sensitivity for breast cancer detection in the Taiwanese population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The THBS1 complex structure ratios provide a reliable and sensitive method for diagnosing breast cancer, distinguishing between healthy individuals and patients with varying stages of the disease, with high sensitivity and specificity, particularly in early detection.
Implementation Method 1
detecting, in a plasma sample from said patient, one or more biomarker values that corresponds to thrombospondin-1 (THBS1) or a THBS1-containing complex structure by performing a capillary electrophoresis under non-reducing conditions
Implementation Method 2
The use of automated capillary electrophoresis and immunodetection to detect and quantify thrombospondin-1 (THBS1) complex structures in plasma samples, employing a capture reagent like antibodies
Data Source
AI summary
Disclosed is a method for diagnosing a patient's breast cancer (BC) health state, or change in BC health state, or for diagnosing risk of BC or the presence of BC in a patient, comprising detecting, in a plasma sample from said patient, one or more biomarker values that corresponds to thrombospondin-1 (THBS1) or a THBS1-containing complex structure by performing a capillary electrophoresis under non-reducing conditions, and assigning the patient as having or not having BC, or having or not having a change in BC health state, or having or not having a risk of BC based on said biomarker values.